We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and characterize new drugs against the RNA methyltransferase METTL3, which he has previously uncovered as a relevant potential target in acute myeloid leukaemia (AML).